PLSE Key Statistics, Chart & Performance
The current stock price of PLSE is 14.6904 USD. In the past month the price increased by 10.02%. In the past year, price decreased by -20.93%.
PLSE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.7 | 222.98B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.43 | 208.85B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.04 | 144.50B | ||
| SYK | STRYKER CORP | 27.65 | 139.28B | ||
| BDX | BECTON DICKINSON AND CO | 14.23 | 58.56B | ||
| IDXX | IDEXX LABORATORIES INC | 56.02 | 56.40B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.47 | 49.92B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.94 | 39.59B | ||
| RMD | RESMED INC | 25.26 | 36.51B | ||
| DXCM | DEXCOM INC | 37.44 | 27.16B | ||
| PODD | INSULET CORP | 64.2 | 20.64B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.71 | 18.77B |
Related stock screener links
About PLSE
Company Profile
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
Company Info
PULSE BIOSCIENCES INC
3957 Point Eden Way
Hayward CALIFORNIA 94545 US
CEO: Darrin R. Uecker
Employees: 75
Phone: 15109064600
PULSE BIOSCIENCES INC / PLSE FAQ
What does PLSE do?
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. The company is headquartered in Hayward, California and currently employs 75 full-time employees. The company went IPO on 2016-05-18. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The company is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
What is the current price of PLSE stock?
The current stock price of PLSE is 14.6904 USD. The price increased by 0.62% in the last trading session.
Does PULSE BIOSCIENCES INC pay dividends?
PLSE does not pay a dividend.
What is the ChartMill rating of PULSE BIOSCIENCES INC stock?
PLSE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the upcoming earnings date for PULSE BIOSCIENCES INC?
PULSE BIOSCIENCES INC (PLSE) will report earnings on 2026-03-25.
Can you provide the short interest for PLSE stock?
The outstanding short interest for PULSE BIOSCIENCES INC (PLSE) is 14.68% of its float.
PLSE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PLSE. When comparing the yearly performance of all stocks, PLSE is a bad performer in the overall market: 84.89% of all stocks are doing better.
PLSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLSE. No worries on liquidiy or solvency for PLSE as it has an excellent financial health rating, but there are worries on the profitability.
PLSE Financial Highlights
Over the last trailing twelve months PLSE reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS decreased by -40.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.71% | ||
| ROE | -80.62% | ||
| Debt/Equity | 0 |
PLSE Forecast & Estimates
7 analysts have analysed PLSE and the average price target is 22.44 USD. This implies a price increase of 52.75% is expected in the next year compared to the current price of 14.6904.